Under the backdrop of changing lifestyle and a sharp increase of aging population, the prevalence of diabetes and overweight/obesity is increasing rapidly. At present, the prevalence of obesity and diabetes in China ranks first in the world, leading to a significant economic burden to China's social development and public health. The association between obesity and diabetes was recognized as early as 50 years ago. Eighty to ninety percent of patients with diabetes are classified as obese. Obesity is considered an independent risk factor for diabetes mellitus. Obese patients often have abnormal glucose metabolism and other components of metabolic syndrome. Currently, bariatric surgery is recognized as the most effective and long-term method for weight loss. In addition to promoting effective weight loss, it can also enhance blood glucose levels and reduce cardiovascular risk. However, some obese patients fail to lose weight after weight loss surgery, and diabetes does not improve. This article reviews the latest epidemiological characteristics of obesity and diabetes, the internal association between obesity and diabetes, the mechanism of weight loss and diabetes relief after weight loss surgery, and the impact of diabetes on weight loss. The aim is to provide a comprehensive understanding of these two chronic metabolic diseases.

Yang Zhang. An Overview of the Progress in Obesity, Diabetes and Bariatric Surgery. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 3: 62-68. https://doi.org/10.25236/IJFM.2024.060310.

[1] World Health Organization, “Obesity: preventing and managing the global epidemic. Report of a WHO consultation,” World Health Organ. Tech. Rep. Ser., vol. 894, pp. i–xii, 1–253, 2000.

[2] World Obesity Atlas 2022 | World Obesity Federation, "One Billion People Globally Estimated to be Living with Obesity by 2030". Accessed: Mar. 29, 2024. Available: https://www.worldobesity.org/r esources/ resource-library/world-obesity-atlas-2022

[3] B. A. Swinburn et al., “The global obesity pandemic: shaped by global drivers and local environments,” Lancet Lond. Engl., vol. 378, no. 9793, pp. 804–814, Aug. 2011, doi: 10.1016/S0140-6736(11) 60813-1.

[4] K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation,” Diabet. Med. J. Br. Diabet. Assoc., vol. 15, no. 7, pp. 539–553, Jul. 1998, doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.

[5] GBD 2021 Diabetes Collaborators, “Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021,” Lancet Lond. Engl., vol. 402, no. 10397, pp. 203–234, Jul. 2023, doi: 10.1016/S0140-6736(23)01301-6.

[6] National Health Commission of the People's republic of China, "Report on the status of Nutrition and Chronic Diseases of Chinese Residents (2020)," Journal of Nutrition, vol. 42, no. 6, p. 521,2020.

[7] E. A. Sims, E. Danforth, E. S. Horton, G. A. Bray, J. A. Glennon, and L. B. Salans, “Endocrine and metabolic effects of experimental obesity in man,” Recent Prog. Horm. Res., vol. 29, pp. 457–496, 1973, doi: 10.1016/b978-0-12-571129-6.50016-6.

[8] H. E. Bays, R. H. Chapman, S. Grandy, and SHIELD Investigators’ Group, “The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys,” Int. J. Clin. Pract., vol. 61, no. 5, pp. 737–747, May 2007, doi: 10.1111/j.1742-1241.2007. 01336.x.

[9] S. Smyth and A. Heron, “Diabetes and obesity: the twin epidemics,” Nat. Med., vol. 12, no. 1, pp. 75–80, Jan. 2006, doi: 10.1038/nm0106-75.

[10] W. Yang et al., “Prevalence of diabetes among men and women in China,” N. Engl. J. Med., vol. 362, no. 12, pp. 1090–1101, Mar. 2010, doi: 10.1056/NEJMoa0908292.

[11] G. A. Colditz, W. C. Willett, A. Rotnitzky, and J. E. Manson, “Weight gain as a risk factor for clinical diabetes mellitus in women,” Ann. Intern. Med., vol. 122, no. 7, pp. 481–486, Apr. 1995, doi: 10.7326/0003-4819-122-7-199504010-00001.

[12] Z. Pataky, E. Bobbioni-Harsch, and A. Golay, “Open questions about metabolically normal obesity,” Int. J. Obes. 2005, vol. 34 Suppl 2, pp. S18-23, Dec. 2010, doi: 10.1038/ijo.2010.235.

[13] G. Marcelin, A. L. M. Silveira, L. B. Martins, A. V. Ferreira, and K. Clément, “Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis,” J. Clin. Invest., vol. 129, no. 10, pp. 4032–4040, Oct. 2019, doi: 10.1172/JCI129192.

[14] H. Yaribeygi, M. Maleki, T. Sathyapalan, T. Jamialahmadi, and A. Sahebkar, “Obesity and Insulin Resistance: A Review of Molecular Interactions,” Curr. Mol. Med., vol. 21, no. 3, pp. 182–193, 2021, doi: 10.2174/1566524020666200812221527.

[15] The Chinese Medical Association, the Journal of the Chinese Medical Association, the General Medicine Branch of the Chinese General Association, the Editorial Committee of the Chinese Journal of General Practitioners, and the Endocrine System Disease Grassroots Diagnosis Guide Writing Expert Group. "Obesity Grassroots Diagnosis and Treatment Guidelines (2019)." Chinese General Practitioner Journal, vol. 19, no. 02. No. 02, Feb. 2020, doi: 10.3760/cma.j.issn. 1671-7368.2020.02.002.

[16] "China Guidelines for Medical Nutrition Treatment of Overweight/Obesity (2021)," Chinese Journal of Frontier Medicine (electronic edition), vol. 13, no. 11, pp. 155, 2021.

[17] D. E. Arterburn, D. A. Telem, R. F. Kushner, and A. P. Courcoulas, “Benefits and Risks of Bariatric Surgery in Adults: A Review,” JAMA, vol. 324, no. 9, pp. 879–887, Sep. 2020, doi: 10.1001/jama. 2020. 12567.

[18] G. Mingrone and L. Castagneto-Gissey, “Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery,” Diabetes Metab., vol. 35, no. 6 Pt 2, pp. 518–523, Dec. 2009, doi: 10.1016/S1262-3636(09)73459-7.

[19] K. A. Carswell et al., “The effect of bariatric surgery on intestinal absorption and transit time,” Obes. Surg., vol. 24, no. 5, pp. 796–805, May 2014, doi: 10.1007/s11695-013-1166-x.

[20] C. Dirksen et al., “Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass,” Neurogastroenterol. Motil., vol. 25, no. 4, pp. 346-e255, Apr. 2013, doi: 10.1111/nmo.12087.

[21] E. A. Odstrcil et al., “The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass,” Am. J. Clin. Nutr., vol. 92, no. 4, pp. 704–713, Oct. 2010, doi: 10.3945/ajcn.2010.29870.

[22] A. Yousseif et al., “Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans,” Obes. Surg., vol. 24, no. 2, pp. 241–252, Feb. 2014, doi: 10.1007/s11695-013-1066-0.

[23] C. R. Hutch and D. Sandoval, “The Role of GLP-1 in the Metabolic Success of Bariatric Surgery,” Endocrinology, vol. 158, no. 12, pp. 4139–4151, Dec. 2017, doi: 10.1210/en.2017-00564.

[24] T. Reinehr, C. L. Roth, G.-H. Schernthaner, H.-P. Kopp, S. Kriwanek, and G. Schernthaner, “Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss,” Obes. Surg., vol. 17, no. 12, pp. 1571–1577, Dec. 2007, doi: 10.1007/s11695-007-9323-8.

[25] E. Paschetta, M. Hvalryg, and G. Musso, “Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders,” Obes. Rev. Off. J. Int. Assoc. Study Obes., vol. 12, no. 10, pp. 813–828, Oct. 2011, doi: 10.1111/j.1467-789X.2011.00897.x.

[26] A. Casajoana et al., “Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy and Greater Curvature Plication,” Obes. Surg., vol. 27, no. 9, pp. 2235–2245, Sep. 2017, doi: 10.1007/s11695-017-2669-7.

[27] N. Šebunova et al., “Changes in adipokine levels and metabolic profiles following bariatric surgery,” BMC Endocr. Disord., vol. 22, no. 1, p. 33, Feb. 2022, doi: 10.1186/s12902-022-00942-7.

[28] “Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor - PubMed.” Accessed: Mar. 29, 2024. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/16473946/

[29] R. E. Steinert et al., “Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial,” Obes. Silver Spring Md, vol. 21, no. 12, pp. E660-668, Dec. 2013, doi: 10.1002/oby.20522.

[30] W. Wang, Z. Cheng, Y. Wang, Y. Dai, X. Zhang, and S. Hu, “Role of Bile Acids in Bariatric Surgery,” Front. Physiol., vol. 10, p. 374, 2019, doi: 10.3389/fphys.2019.00374.

[31] T. P. M. Scheithauer, G. M. Dallinga-Thie, W. M. de Vos, M. Nieuwdorp, and D. H. van Raalte, “Causality of small and large intestinal microbiota in weight regulation and insulin resistance,” Mol. Metab., vol. 5, no. 9, pp. 759–770, Sep. 2016, doi: 10.1016/j.molmet.2016.06.002.

[32] Y. Kim et al., “Association between the Blautia/Bacteroides Ratio and Altered Body Mass Index after Bariatric Surgery,” Endocrinol. Metab. Seoul Korea, vol. 37, no. 3, pp. 475–486, Jun. 2022, doi: 10.3803/EnM.2022.1481.

[33] Linqing Zhu, Xiaoya Wu, Jialin Zhang, "Progress in the changes of intestinal flora after weight loss metabolic surgery and its impact on postoperative complications," Chinese General Basic and Clinical Journal, vol. 30, no. 11, pp. 1378-1383, 2023.

[34] J. Yadav et al., “Gut microbiome modified by bariatric surgery improves insulin sensitivity and correlates with increased brown fat activity and energy expenditure,” Cell Rep. Med., vol. 4, no. 5, p. 101051, May 2023, doi: 10.1016/j.xcrm.2023.101051.

[35] J. Y. Park, “Weight Loss Prediction after Metabolic and Bariatric Surgery,” J. Obes. Metab. Syndr., vol. 32, no. 1, pp. 46–54, Mar. 2023, doi: 10.7570/jomes23008.

[36] Y. Ma et al., “Predictors of weight status following laparoscopic gastric bypass,” Obes. Surg., vol. 16, no. 9, pp. 1227–1231, Sep. 2006, doi: 10.1381/096089206778392284.

[37] E. Bobbioni-Harsch et al., “Factors influencing energy intake and body weight loss after gastric bypass,” Eur. J. Clin. Nutr., vol. 56, no. 6, pp. 551–556, Jun. 2002, doi: 10.1038/sj.ejcn.1601357.

[38] E. Rebelos, D. Moriconi, M.-J. Honka, M. Anselmino, and M. Nannipieri, “Decreased Weight Loss Following Bariatric Surgery in Patients with Type 2 Diabetes,” Obes. Surg., vol. 33, no. 1, pp. 179–187, Jan. 2023, doi: 10.1007/s11695-022-06350-z.

[39] G. B. Melton, K. E. Steele, M. A. Schweitzer, A. O. Lidor, and T. H. Magnuson, “Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes,” J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract, vol. 12, no. 2, pp. 250–255, Feb. 2008, doi: 10.1007/s11605-007-0427-1.

[40] E. Ortega et al., “Predictive factors of excess body weight loss 1 year after laparoscopic bariatric surgery,” Surg. Endosc., vol. 26, no. 6, pp. 1744–1750, Jun. 2012, doi: 10.1007/s00464-011-2104-4.

[41] M. T. Hayes, L. A. Hunt, J. Foo, Y. Tychinskaya, and R. S. Stubbs, “A model for predicting the resolution of type 2 diabetes in severely obese subjects following Roux-en Y gastric bypass surgery,” Obes. Surg., vol. 21, no. 7, pp. 910–916, Jul. 2011, doi: 10.1007/s11695-011-0370-9.

[42] A. M. Ramos-Leví et al., “C-peptide levels predict type 2 diabetes remission after bariatric surgery,” Nutr. Hosp., vol. 28, no. 5, pp. 1599–1603, 2013, doi: 10.3305/nh.2013.28.5.6554.